Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline Nor Post-SBRT Pulmonary Function Are Associated with Worse Overall Survival
Conclusions: As the largest cohort of patients with prospective follow-up PFT evaluation after lung SBRT, this supports the safety of SBRT in this population of predominantly medically inoperable patients. While statistically significant, nearly all declines in PFTs would be rated as a grade 1 on the Radiation Therapy Oncology Group scale, demonstrating safety. PFT declines were not associated with worse overall survival. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
Conclusions: Treatment of LC with EGFR TKI, cytotoxic chemotherapy, or WBRT in selected patients is associated with prolong survival period. These treatment options, especially EGFR TKIs, should be studied in patients with EGFR mutation-positive NSCLC and LC. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non–Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Conclusions: Third-/fourth-line sorafenib therapy did not significantly increase OS in patients with relapsed/refractory NSCLC, despite significantly increasing PFS. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor
Conclusion: Acquired resistance mechanisms of AZD9291 in patients with EGFRT790M-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFRT790M-mutant clones plus alternative pathway activation or histologic transformation and EGFR ligand–dependent activation. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Conclusions: The expression of PD-1 and its ligands PD-L1 and PD-L2 is heterogeneous within KRAS-mutant NSCLC and suggests an inducible expression of PD-L1 by smoking. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma
Conclusion: Concurrent CRT resulted in shorter progression-free survival in EGFR-mutant stage III adenocarcinoma patients than in wild-type patients, mainly because of distant metastasis relapse, regardless of better local control. Because of these distinct biological features, a different strategy, including EGFR-tyrosine kinase inhibitors for EGFR-mutant locally advanced adenocarcinoma patients receiving definitive CRT may be needed. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
Conclusion: A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas. There was no evidence that clinical benefit from EGFR TKI monotherapy is affected by a concurrent PIK3CA mutation in EGFR-mutant lung cancers. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Increasing Physical Activity and Exercise in Lung Cancer: Reviewing Safety, Benefits, and Application: Erratum
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Errata Source Type: research
Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of Radiation-Induced Activation of Macrophages and Neutrophils
Conclusions: Soy isoflavones inhibit the infiltration and activation of macrophages and neutrophils induced by radiation in lungs. Soy isoflavones-mediated modulation of macrophage and neutrophil responses to radiation may contribute to a mechanism of resolution of radiation-induced chronic inflammation leading to radioprotection of lung tissue. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Identifying Targeted Strategies to Improve Smoking Cessation Support for Cancer Patients: Erratum
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Errata Source Type: research
A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System
Conclusions: This is the first NSCLC prognosis model for quick risk assessment within the Military Health System. After external validation, the model can be translated into clinical use both as a web-based tool and through mobile applications easily accessible to physicians, patients, and researchers. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer
Methods of harnessing the immune system to treat cancer have been investigated for decades, but yielded little clinical progress. However, in recent years, novel drugs that allow immune recognition and destruction of tumor cells are emerging as potent cancer therapies. Building upon previous immunotherapy strategies that included therapeutic vaccines, recombinant cytokines, and other immunostimulatory agents, newer immunotherapy agents targeting immune checkpoints including programmed cell death 1, programmed cell death ligand-1, and cytotoxic T-lymphocyte-associated protein 4, among others, have garnered substantial enthu...
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: State of the Art: Concise Review Source Type: research
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer
Conclusions: Current N descriptors adequately predict the prognosis and therefore should be maintained in the forthcoming staging system. Furthermore, we recommend that physicians record the number of metastatic lymph nodes (or stations) and to further classify the N category using new descriptors, such as N1a, N1b, N2a, N2b, and N3, for further testing. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: State of the Art: Concise Review Source Type: research
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Conclusions: Entrectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrangements, including those with central nervous system metastases. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Brief Report Source Type: research
The MISSION: Impossible? No, the Journey Should Continue with Better Targeting!
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - November 24, 2015 Category: Cancer & Oncology Tags: Editorials Source Type: research
